Dengue
Gabriela Paz‐Baileya b✉, Laura E. Adamsb, Jacqueline L. Deenc, Kathryn B. Andersond, Leah C. Katzelnicke
- aCenters for Disease Control and Prevention, San Juan, Puerto Rico. Electronic address: gmb5@cdc.gov
- bCenters for Disease Control and Prevention, San Juan, Puerto Rico
- cInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines, Manila, Philippines
- dDepartment of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA
- eViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Dengue, caused by four closely related viruses, is a growing global public health concern, with outbreaks capable of overwhelming health-care systems and disrupting economies. Dengue is endemic in more than 100 countries across tropical and subtropical regions worldwide, and the expanding range of the mosquito vector, affected in part by climate change, increases risk in new areas such as Spain, Portugal, and the southern USA, while emerging evidence points to silent epidemics in Africa. Substantial advances in our understanding of the virus, immune responses, and disease progression have been made within the past decade. Novel interventions have emerged, including partially effective vaccines and innovative mosquito control strategies, although a reliable immune correlate of protection remains a challenge for the assessment of vaccines. These developments mark the beginning of a new era in dengue prevention and control, offering promise in addressing this pressing global health issue.